Lucius Ovisibat – Acheter en ligne

EUR 329.33

3,000+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

Indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC), and in patients 12 months of age and older with Alagille syndrome (ALGS).

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
400mcg*30 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Catégories : , Marque :

Informations produit

Nom anglais
Odevixibat
Nom générique
Odevixibat

Caractéristiques

Spécification
400mcg*30 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC), and in patients 12 months of age and older with Alagille syndrome (ALGS).

Mécanisme d’action

IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]

Pharmacologie

12.1 Mecanisme d action IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]

Posologie

2.1 3 PFIC BYLVAY 40 mcg/kg, , 1 3 , 40 mcg/kg , 120 mcg/kg, 6 mg BYLVAY 19.5 kg BYLVAY 19.5 kg

Precautions

5.1 BYLVAY (DILI) PFIC ALGS , 6 DILI ,2 ALGS PFIC , 6 8 , , BYLVAY ,

Contre-indications

IBAT BYLVAY , [ Precautions 5.1 ]

Interactions médicamenteuses

7.1 , BYLVAY 4 4 [ Posologie (2.3)] , BYLVAY

Effets indésirables

[ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 , , PFIC 1 24 , BYLVAY 40 mcg/kg 120 mcg/kg [ (14.1)]

Package Insert

Ingredients

11 BYLVAY BYLVAY IBAT , (2S)-2-{[(2R)-2-(2-{[3,3- -7-( )-1,1- -5- -2,3,4,5- -1H-1λ 6 ,2,5- -8- ] } )-2-(4- ) ] } , , C 37 H 48 N 4 O 8 S 2 × 1.5 H 2 O, 768.0 g/mol 740.9 g/mol pH , pH BYLVAY , , 200 600

Indications

Indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC), and in patients 12 months of age and older with Alagille syndrome (ALGS).

Posologie

2.1 3 PFIC BYLVAY 40 mcg/kg, , 1 3 , 40 mcg/kg , 120 mcg/kg, 6 mg BYLVAY 19.5 kg BYLVAY 19.5 kg

Effets indésirables

[ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 , , PFIC 1 24 , BYLVAY 40 mcg/kg 120 mcg/kg [ (14.1)]

Contre-indications

IBAT BYLVAY , [ Precautions 5.1 ]

Precautions

5.1 BYLVAY (DILI) PFIC ALGS , 6 DILI ,2 ALGS PFIC , 6 8 , , BYLVAY ,

Use in Pregnancy and Lactation

8.1 BYLVAY , ,BYLVAY , odevixibat , 2.1

Interactions médicamenteuses

7.1 , BYLVAY 4 4 [ Posologie (2.3)] , BYLVAY

Clinical Pharmacology

12 12.1 Mecanisme d action (IBAT) (PFIC) (ALGS) PFIC PFIC ALGS , IBAT , , [ (12.2)] 12.2 PFIC ALGS

Pharmacology and Toxicology

13 13.1 2 , 100 mg/kg/ odevixibat , AUC 231 459 Ames 1000 mg/kg/

Clinical Studies

14 14.1 PFIC BYLVAY 1 (NCT03566238) , 24 1 62 6 17 , PFIC 1 2 , 1 , ABCB11 BSEP INR 1.4 ALT ULN 10 n=20 40 mcg/kg n=23 120 mcg/kg n=19

Avis produit (15)

Filtre : Tous les avis
4.8★★★★★
15 avis clients12 achats verifies
+o***e· 3周前
★★★★
+t***3· 1个月前
Achat verifie
★★★★★

Description

Indications

Indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC), and in patients 12 months of age and older with Alagille syndrome (ALGS).

Mécanisme d’action

IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]

Pharmacologie

12.1 Mecanisme d action IBAT PFIC ALGS PFIC PFIC ALGS , IBAT , , [ 12.2 ]

Posologie

2.1 3 PFIC BYLVAY 40 mcg/kg, , 1 3 , 40 mcg/kg , 120 mcg/kg, 6 mg BYLVAY 19.5 kg BYLVAY 19.5 kg

Precautions

5.1 BYLVAY (DILI) PFIC ALGS , 6 DILI ,2 ALGS PFIC , 6 8 , , BYLVAY ,

Contre-indications

IBAT BYLVAY , [ Precautions 5.1 ]

Interactions médicamenteuses

7.1 , BYLVAY 4 4 [ Posologie (2.3)] , BYLVAY

Effets indésirables

[ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 , , PFIC 1 24 , BYLVAY 40 mcg/kg 120 mcg/kg [ (14.1)]